Christopher Isham is VP, Washington Bureau Chief at CBS News

Updates

Four Patients Die in Xarelto Study of 1,000

The results of a recently-concluded study purport to show that Xarelto (rivaroxaban) is as safe as warfarin for patients atrial fibrillation patients awaiting elective cardioversion even though four persons included in the study died. According to an article published on September 2 at medpagetoday.com atrial fibrillation patients awaiting elective cardioversion… Read more

Bayer Aims to Expand Xarelto Use Despite Known Risks

Drug manufacturer Bayer has made public plans to launch new studies as a step toward seeking approval of its anticoagulant Xarelto for additional uses. According to a Reuters report Xarelto manufacturer Bayer is going to be testing the drug—currently very popular as a treatment for preventing strokes—on patients with “embolic stroke… Read more

Doctors Prescribing More New Oral Anticoagulants Despite Known Risks

A new study shows that physicians are prescribing Pradaxa Xarelto and Apixaban in higher numbers than ever notwithstanding research linking these blood-thinning drugs to potentially fatal adverse side effects. According to an analysis published in the American Journal of Medicine physicians have been prescribing newer anticoagulants such as Pradaxa… Read more

Pradaxa Maker Sales Drop

According to FiercePharma “The Germany-based company forecasts revenues will be down for the year as well but it says by getting its house in order its finances can improve after that. It has settled some nagging litigation and sold some assets and it’s about ready to launch some newly approved drugs.”… Read more

Pradaxa MDL Court Orders Establishment of Qualified Settlement Fund

According to Case Management Order Number 82 filed on August 13 in IN RE: PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION the federal multidistrict litigation consolidating Pradaxa lawsuits against drugmaker Boehringer Ingelheim Pharmaceuticals Inc. a “qualified settlement fund” is established and a fund administrator appointed in order to effectuate the… Read more

British Regulator Launches “Learning Module” on Oral Anticoagulants Including Xarelto

According to a press release dated August 5 and published by the MHRA: “Anticoagulants are vital medicines for treating and preventing blood clots. However if the patient is not managed correctly their side effects can lead to a small number of people needing hospital treatment. With the right precautions many of these side… Read more

Xarelto Found to Be More Cost-Effective Than Other Drugs

According to an article published in the July 2014 issue of Pharmacy Practice News rivaroxaban (Xarelto) “was more cost-effective than other anticoagulants for inpatient use in two retrospective studies that included patients undergoing joint replacement as well as those with atrial fibrillation or venous thromboembolism. One expert predicted however that insurance issues… Read more

Anticoagulant Drug Xarelto Passes Pradaxa in Number of Reported Alleged Injuries

In 2013 the U.S. FDA received several hundred adverse event reports submitted by individuals who claimed to have a serious adverse side effect while taking Xarelto (rivaroxaban) as compared to a lower number for Pradaxa (dabigatran). Data show that the number of persons being prescribed these blood thinning drugs is estimated at about… Read more